Kornimate/medical-research-clean huggingface dataset:
prehabilitation for pelvic cancer: changes in setup variability

Conditions: Pelvic Cancer

Summary: the investigators hypothesize that two pelvic relaxation exercises will be feasible and safe to perform by subjects daily before radiation during the participant's treatment and will decrease variability of sacral slope measurements on daily port films. the investigators will observe trends in the daily variability and change in the sacral slope in each participant to determine if this could decrease variability. the investigators will compare these measurements to a retrospective cohort that did not have the exercises, but did demonstrate variability. reducing set-up variability (which inadvertently occurs during radiation) is important to improve radiation targets and diminish potential adverse effects. the investigators will query participants for objective and subjective feedback on the exercises and record frequency and duration of the two exercises.


Eligibility criteria:
inclusion criteria: * patients will be \>21 yrs of age and will have an oncologic diagnosis that requires a course of pelvic radiation therapy for a minimum of 5 weeks. * they will have an ecog performance status (this scale, developed by the eastern cooperative oncology group (ecog), now part of the ecog-acrin (american college of radiology imaging network) cancer research group, describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.)) of 1 or better as determined by patient history. * they will be ambulatory without needing any ambulatory aids such as a cane or walker. * both men and women will be eligible as there is no significant anatomical difference in sacral slope measurement. joint replacement patients will not be excluded. exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * non-english speaking subjects

Keywords: exercise
a pilot trial to determine the extent of inter- and intra-treatment organ motion using active breathing control device (abc) in patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a study to assess the motion of pancreatic tumors during radiation therapy using computed tomography (ct) scans and an active breathing control (abc) device.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * a working diagnosis (with or without histologic confirmation) of pancreatic cancer * a plan to treat with radiotherapy (or chemoradiotherapy) * patients must have fiducial marker(s) endoscopically placed within the pancreas for clinical treatment. exclusion criteria: * previous abdominal radiotherapy. * patients with a history of major abdominal surgery. * patients who are pregnant.
experience of the patient treated with trastuzumab (herceptin ®) as adjuvant for breast cancer

Conditions: Breast Cancer

Summary: many studies have been devoted to the quality of life of patients during adjuvant chemotherapy for breast cancer by highlighting fatigue, psychological distress and impact on the immediate environment (spouse, children) during this difficult time for women. curiously, no study to date has been submitted or published about how women with a one-year treatment "extra" herceptin ® live this period in terms of quality of life, in terms of psychological impact for themselves and their families. the investigators have no more data on how often they return to work during this treatment or on the psycho-social parameters which underpin them. it therefore seemed interesting to "give a spotlight" on this particular period in these women her2 + by comparing a patient population of same age receiving the same adjuvant but with no herceptin ®.


Eligibility criteria:
inclusion criteria: * women aged over 18 * invasive breast carcinoma confirmed histologically * non-metastatic cancer * surgery of the primary tumor performed (mastectomy or lumpectomy) and associated with an audit axillary (sentinel node and / or axillary dissection) * patient should receive their last course of adjuvant chemotherapy (3 fec and 3 taxotere) * patients not receiving the third course of taxotere because of toxicities may be included in the fifth course of chemotherapy is the second of taxotere * for the group herceptin ®: her2 overexpression without contraindication to treatment administration * for the control group: no indication for herceptin ® * radiation therapy and / or adjuvant hormonal therapy allowed * free and informed consent signed exclusion criteria: * women under 18 or over 60 years * histology other than adenocarcinoma * metastatic breast cancer * chemotherapy neoadjuvant * surgery of the primary tumor unrealized * lack of adjuvant chemotherapy with taxotere 3 fec and 3 * patients with a history of malignancy within 5 years, outside of a basal cell cancer or cancer of the cervix treated and cured * patient under guardianship or unable to give informed consent, * pregnant or lactating * patient unable to undergo a medical for geographical, social or psychopathological

Keywords: herceptin breast cancer quality of life fatigue
network effects of therapeutic deep brain stimulation

Conditions: Intractable Epilepsy

Summary: the purpose of this study is to map the acute, short-term cortical evoked responses to thalamic electrical stimulation in persons with intractable epilepsy


Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy * undergoing neuromodulation therapy with clinically implanted neuromodulation devices (dbs, rns) * followed in the outpatient epilepsy clinic exclusion criteria: * pregnant women * active psychosis, major depression, or suicidal ideation in the preceding year * intelligence quotient (iq) less than 70 as measured by clinical neuropsychological evaluation * do not agree to share their medical records for research purposes

Keywords: deep brain stimulation (dbs) neuromodulation therapy responsive neurostimulation (rns)
safety and efficacy of chimeric antigen receptor t lymphocytes for patients with intermediate and advanced tumors

Conditions: Melanoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma

Summary: this was a single arm, open-label, single center, cohort study to determine the efficacy and safety of amt-116 car-t cells in patients with moderate or far advanced non-small cell lung carcinoma (nsclc) and squamous cell cancer of the head and neck (hnscc)，amt-253 car-t cells in patients with moderate or far advanced melanoma.


Eligibility criteria:
inclusion criteria: * age 18-70 years old, both men and women, and the survival period is more than 6 months. * at least one assessable focus, failure of previous multi-line treatment or stable condition after treatment. * patients with melanoma confirmed by histopathology, patients with non-small cell lung cancer(squamous carcinoma) and head and neck squamous cell carcinoma. * the surgically removed pathological tissue can be used for immunohistochemical detection of target protein (paraffin section should be within 5 years), and the positive expression of target protein in line with pathological diagnosis (immunohistochemical staining + + or + + +). * sufficient venous access for blood sampling and venous blood sampling, no contraindications for lymphocyte collection. * routine blood examination: white blood cell count (wbc) ≥ 3 × 10\^9 / l, lymphocyte count (ly) ≥ 0.8 × 10\^9 / l, hemoglobin (hb) ≥ 90g / l, platelet (plt) ≥ 80 × 10\^9/l. * liver and kidney function: alanine aminotransferase and aspartate aminotransferase \< 3 uln, total bilirubin (tbil) \< 1.5 uln, serum creatinine (scr) \< 2 uln. * the subjects voluntarily joined the study, signed the informed consent form, had good compliance and cooperated with the follow-up. exclusion criteria: * active hepatitis b or hepatitis c virus, hiv infection, or other unhealed active infections. * patients with second tumor. * patients previously treated with car-t cells. * requiring long-term use of immunosuppressants for any reason. * any serious and uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, crohn's disease and temporal arteritis. * subjects with severe heart, lung, liver and kidney dysfunction or severe lung diseases. * current systemic use of steroid cells (except for recent or current use of inhaled steroids). * pregnant and lactating subjects. * allergic to immunotherapy and related cells. * subjects with a history of organ transplantation or waiting for organ transplantation. * after evaluation, the investigator considered that the subjects were unable or unwilling to comply with the requirements of the study protocol.
use of thermacare heat wraps and ibuprofen as an adjunct to physical therapy for neck pain

Conditions: Heat; Pain

Summary: objective- to see if the use of heat at home between physical therapy sessions results in better therapy outcomes in people with acute neck pain. setting: physical therapy outpatient rehabilitation center participants: 90 people with acute nonspecific neck pain broken into 4 groups. intervention: all subjects will undergo 45 minutes of therapy 2 times per week for 2 weeks. all subjects will accomplish 1 hour of therapeutic exercise at home on days when there is no therapy. thirty of the subjects will use thermacare neck wraps before home exercise, 30 used ibuprofen plus thermacare neck wraps before home exercise, 15 will use a sham heat wrap and an ibuprofen placebo each day (1200 mg / day) and the last 15 will be controls with conventional physical therapy.

neck pain patients admitted to an outpatient physical therapy program will be randomly assigned to either a control or 3 experimental groups. an initial evaluation and rehabilitation program will be established which includes a home exercise program. therapy will be 2 days per week for 2 weeks. thirty of the subjects will use thermacare continuous heat neck wraps applied for 6 hours before home exercise, 30 will use ibuprofen (1200 mg /day given in 3 dosages) plus thermacare neck wraps before home exercise, 15 will use a sham heat wrap and a ibuprofen placebo each day and the last 15 will have conventional therapy. intervention with heat or ibuprofen will be used on days that they are not being treated in the clinic. all groups will be evaluated initially and after 2 weeks. they will be given home exercise and heat compliance logs and analog visual pain scales to be filled out each night before exercise and, if they used heat, before and after heat will be applied. the physical therapist will also be asked to evaluate their home compliance, pain and the benefit to them from the heat packs. subjects will complete a neck disability questionnaire at the beginning and end of the study. at the end of the two weeks of treatment, a multivariate anova will be performed to compare changes in home exercise compliance, functional level, pain level, range of motion, and strength. a statistical level of p≤.05 is considered predictive of a difference between groups.

Eligibility criteria:
inclusion criteria: * age 18-80 years exclusion criteria: * those with neck pain caused by fractures or spinal damage * those who have undergone neck surgery within the last year * those with radiculopathy or those with diagnosed diabetes were excluded from this study
evaluation of neuromuscular morphometry of the vaginal wall

Conditions: Pelvic Organ Prolapse

Summary: in this prospective study, women aged between 40 and 75 years who had not undergone any vaginal surgery and had not undergone any abdominal prolapse surgery were included. thirty-one women diagnosed with rectocele on examination were included in the study group. thirty-one patients who underwent vaginal intervention and hysterectomy for reasons other than rectocele (colposcopy, conization, etc.) without anterior or posterior wall prolapse were included in the control group.

in this prospective study,who had not undergone any vaginal surgery and had not undergone any abdominal prolapse surgery were included. thirty-one women diagnosed with rectocele on examination were included in the study group. thirty-one patients who underwent vaginal intervention and hysterectomy for reasons other than rectocele (colposcopy, conization, etc.) without anterior or posterior wall prolapse were included in the control group. biopsy material was obtained from the epithelium of the posterior wall of the vagina, including the fascia that fits the ap point. immunohistochemical staining with protein gene product 9.5 and smooth muscle α-actin was performed in the pathology laboratory. the epithelial thickness measurement and smooth muscle density parameters obtained with these immunohistochemical stainings were compared between the two groups. the collected data were analyzed using spss 23 package program

Eligibility criteria:
inclusion criteria: * patients aged 40-75 years * patients operated for prolapse * patients who did not have prolapse and who would undergo vaginal intervention for other gynecologic reasons were designed to constitute the control group. * who had not undergone any vaginal surgery, had not undergone any abdominal uterine suspension surgery, had posterior wall prolapse, and for whom surgery was planned. exclusion criteria: * patients whose age was not suitable * who had previously undergone vaginal surgery, who had undergone abdominal surgery and a uterine suspension surgery, who were not suitable for the specified examination conditions * who had undergone rectocele surgery, urinary incontinence, or bladder surgery

Keywords: posterior vaginal wall prolapse smooth muscle actin
internet cbt for antenatal depression

Conditions: Antenatal Depression

Summary: pregnant women in pregnancy week 8-29 screening positive for antenatal depression will be randomized to either choose or to be allotted by chance to different forms of diagnostic assessment; i.e. telephone, video or face-to-face assessment. those diagnosed with mild to moderate major depression will then be randomized to treatment with therapist-guided internet-delivered cognitive behavioral therapy (icbt) adapted for women suffering from antenatal depression or to the same treatment with addition of up to three contacts with extra support by a midwife or experienced perinatal mental health nurse. the primary aim is to assess whether extrasupport in addition to internet-guided pregnancy adapted icbt decreases depressive symptoms more than internet-guided pregnancy adapted icbt only. secondary aims include effects of extrasupport and assessment mode on treatment satisfaction, fidelity and credibility.


Eligibility criteria:
inclusion criteria: * mild to moderate major depression * pregnant at treatment start * regular contact with maternity mental health clinic * \> 18 years old * being able to start the treatment earliest in gestational week 8 and latest in gestational week 30 * stable medication for depression and/or other psychiatric conditions for at least 3 weeks. * being able to participate in the treatment during the treatment time and having access to and being able to use the internet and mobile phone during the treatment time * being able to understand the swedish language orally and in writing exclusion criteria: * montgomery-åsberg depression rating scale-self report version (madrs-s) score below 15 (symptoms of depression to low) or above 35 (severe depression) * high risk of self harm or suicide (based on semi-structured clinical suicide risk assessment) * psychiatric comorbidity, disability, somatic disorder, or pregnancy complications that prevent treatment participation or that can be negatively affected or compose a risk for the fetus by treatment participation * ongoing psychological treatment with similar content

Keywords: cognitive behavior therapy internet treatment self-help treatment perinatal support
rescue high frequency oscillatory ventilation in newborns who do not respond to conventional ventilation

Conditions: Acute Mechanical Ventilatory Failure

Summary: although high frequency oscillatory ventilation (hfov) has been used in case of unresponsive to conventional mechanical ventilation both in children and newborns, there is no data on its success and the factors that affect its success in the literature.

although high frequency oscillatory ventilation (hfov) has been used in case of unresponsive to conventional mechanical ventilation both in children and newborns, there is no data on its success and the factors that affect its success in the literature. the aim of the study is to define the factors that affect the success of hfov in newborns who do not respond to conventional mechanical ventilation through an online registry among neonatal intensive care units in turkey.

Eligibility criteria:
inclusion criteria: * patients switched to hfov in case of unresponse to conventional ventilation * stay on hfov for at least 4 h exclusion criteria: * any congenital anomaly * hfov duration less then 4 h

Keywords: high frequency oscillatory ventilation rescue newborn
non-comparative study of fluconazole in patients with serious mycoses and who cannot be treated with conventional antifungal therapy

Conditions: Candidiasis; Mycoses; HIV Infections

Summary: the primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal therapy or have had unacceptable reactions to conventional antifungal therapy, and who are ineligible for other established fluconazole clinical trial protocols.


Eligibility criteria:
exclusion criteria co-existing condition: a patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole. a patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole. amended: * 900207 open only to unapproved indications and/or age ranges. * original design: * patients with clinically established serious or life-threatening systemic fungal disease will be considered if conventional fungal therapy is not an acceptable alternative. unacceptability of conventional therapy is defined as: * failure of conventional therapy to control or eradicate infection after appropriate trial(s) of generally accepted regimen(s). * serious and unacceptable untoward reaction(s) to conventional antifungal therapy. * or a major contraindication to the use of conventional antifungal therapy. * the patient must be ineligible or have no access to other established fluconazole investigational protocols. the final judgment of patient acceptability for inclusion lies with the pfizer clinical monitor.

Keywords: mycoses drugs, investigational fluconazole
remote monitoring with health-coaching for lifestyle changes in patients with lung cancer related fatigue

Conditions: Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Summary: this clinical trial investigates the effectiveness of a remote monitoring program for lifestyle changes in patients with lung cancer related fatigue (crf). fatigue is a common symptom of lung cancer and a side-effect of cancer treatments. crf has a negative impact on patients' quality of life, daily activities, employment, social relationships and mood. health coaches enable patients to develop and achieve self-determined wellness goals and assist patients to use their insight, personal strengths, goal setting, action steps, and accountability toward achieving healthy lifestyle changes. remote monitoring with health-coaching may help relieve lung cancer related fatigue and increase the quality of life in cancer patients.

primary objective: i. to assess the effect of the remote-monitoring program on patient reported fatigue by administering the brief fatigue inventory (bfi), functional assessment of cancer therapy fatigue (fact-f), functional assessment of cancer therapy- lung (fact-l) and the modified fatigue impact scale (mfis). outline: patients undergo routine exercise using a remote monitoring system (garmin vívofit activity monitor, nonin 3150 wristox2 pulse oximeter, and an android tablet) over 30 minutes at least 6 days per week and complete daily questionnaires over 20 minutes for 12 weeks. patients also receive health coaching telephone calls over 5-20 minutes once a week for 12 weeks. at the end of the 12 weeks, patients complete an audio taped telephone interview.

Eligibility criteria:
inclusion criteria: * diagnosed with advanced lung non-small cell carcinoma (nsclc) being treated with any line of non-curative intent, systemic treatment. * eastern cooperative oncology group (ecog) performance status from 0 (asymptomatic) to 2. * the ability to read and respond to questions in english or spanish * receiving primary cancer care at mayo clinic, rochester or mayo clinic health system (mchs). * age \> 18 years. * life expectancy at least 6 months. * moderate or higher fatigue (\>= 4) on a scale of 0-10 based on fatigue rating to question: rate your average fatigue over the last week, where 0 is no fatigue and 10 is extreme fatigue. exclusion criteria: * they have cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation.
development and validation of a real-time prediction model for acute kidney injury in hospitalized patients

Conditions: Prediction Model

Summary: early prediction of acute kidney injury (aki) may provide a crucial opportunity for aki prevention. to date, no prediction model targeting aki among general hospitalized patients in developing countries has been published. we developed a simple, real-time, interpretable aki prediction model for general hospitalized patients from a large tertiary hospital in china, and validated it across five independent, geographically distinct, different tiered hospitals.

early prediction of acute kidney injury (aki) may provide a crucial opportunity for aki prevention. to date, no prediction model targeting aki among general hospitalized patients in developing countries has been published. we developed a simple, real-time, interpretable aki prediction model for general hospitalized patients from a large tertiary hospital in china using the machine learning technique, and then validated the performance of the prediction model across five independent, geographically distinct, different tiered hospitals in china.

Eligibility criteria:
inclusion criteria: * adult patients (18 years and older) admitted to five hospitals during the study period exclusion criteria: * have less than 2 documented serum creatinine (scr) measurements during hospitalization * being diagnosed with end-stage renal disease (esrd) * maintained on dialysis or had an initial scr greater than or equal to 4.0 mg/dl at admission * developed aki prior to admission or within 24 hours after admission * length of stay shorter than 24 hours * underwent kidney transplantation or nephrectomy during hospitalization * with all scr measurements lower than or equal to 0.6 mg/dl from 90 days prior to admission until discharge.